Media

Strongbridge Biopharma Receives Notice of Allowance from U.S. Patent and Trademark Office for New Patent Covering RECORLEV™ (levoketoconazole) for the Treatment of Cushing’s Syndrome

Strongbridge Biopharma Receives Notice of Allowance from U.S. Patent and Trademark Office for New Patent Covering RECORLEV™ (levoketoconazole) for the Treatment of Cushing’s Syndrome

Strongbridge Biopharma plc Announces Acquisition of the U.S. and Canadian Rights to MACRILEN™ (macimorelin) from Aeterna Zentaris

GenSight Biologics receives MHRA approval to initiate Phase I/II PIONEER clinical trial of GS030 gene therapy in Retinitis Pigmentosa

Pulmonx Submits Premarket Approval (PMA) Application to U.S. FDA for Zephyr Endobronchial Valve as Treatment for Emphysema

BioClin Therapeutics Appoints Graeme Currie, Ph.D., as Chief Operating Officer and Esteban (Steve) Abella, M.D., as Chief Medical Officer

Nexstim enrols last patient in supplementary Phase III E-FIT trial

Altimmune Elects Mitchel Sayare, Ph.D. as Chairman of its Board of Directors